Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection

Bibliography

• Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372(9635):293-9
   PubMed Web of Science ®Google Scholar
• Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 2014;58(9):1297-307
   PubMed Web of Science ®Google Scholar
• DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2014.1-282 Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [cited 22 December 2014]
   Google Scholar
• EACS. European AIDS Clinical Society. European Guidelines for treatment of HIV infected adults in Europe. 2014. Version 7.1 Available from: http://www.eacsociety.org/files/guidelines_english_71_141204.pdf [cited 4 December 2014]
   Google Scholar
• Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312(4):410-25
   PubMed Web of Science ®Google Scholar
• EMA. Triumeq; Summary of Product Characteristics. 2014
   Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369(19):1807-18
   PubMed Web of Science ®Google Scholar
• Walmsley S, Berenguer J, Khuong-Josses MA, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA 2014
   Google Scholar
• Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009;49:377-94
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4(3):236-48
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55(2):813-21
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47(6):351-71
   PubMed Web of Science ®Google Scholar
• Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36(1):41-66
   PubMed Web of Science ®Google Scholar
• Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol 2010;6(1):105-14
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54(1):254-8
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25(14):1737-45
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12(2):111-18
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381(9868):735-43
   PubMed Web of Science ®Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis 2014;59(7):1032-7
   PubMed Web of Science ®Google Scholar
• Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013;41(2):353-61
   PubMed Web of Science ®Google Scholar
• Weller S, Chen S, Borland J, et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr 2014;66(4):393-8
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56(3):1627-9
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Lou Y, Thompson NF, et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol 2001;41(3):277-88
   PubMed Web of Science ®Google Scholar
• Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999;19(8):932-42
   PubMed Web of Science ®Google Scholar
• Baker KL, Lou Y, Yuen GJ. The bioequivalence and effect of food of a new once-a day fixed dose combination tablet of abacavir (ABC) and lamivudine (3TC). >44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC 2004
   Google Scholar
• Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother 2013;57(8):3536-46
   PubMed Web of Science ®Google Scholar
• Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics 2014;15(1):9-16
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Savina PM, et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacology in Drug Development 2013;2(4):342-48
   Google Scholar
• Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996;40(6):1514-19
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Aymard G, et al. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron 2001;89(1):62-7
   PubMed Web of Science ®Google Scholar
• Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol 2014;70(1):29-35
   PubMed Web of Science ®Google Scholar
• Zong J, Borland J, Jerva F, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Int AIDS Soc 2014;17(4 Suppl 3):19584
   PubMedGoogle Scholar
• Song I, Borland J, Arya N, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 2014;1-7
   Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66(7):1567-72
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013;62(1):21-7
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol 2014;70(10):1173-9
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother 2014;58(11):6696-700
   PubMed Web of Science ®Google Scholar
• Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013;57(11):5472-7
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor. S/GSK1349572. Br J Clin Pharmacol 2011;72(1):103-8
   Web of Science ®Google Scholar
• Song I, Min SS, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 2011;51(2):237-42
   PubMed Web of Science ®Google Scholar
• Johnson M, Borland J, Chen S, et al. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J Clin Pharmacol 2014;78(5):1043-9
   PubMed Web of Science ®Google Scholar
• Song IH, Borland J, Chen S, et al. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013;57(9):4394-7
   PubMed Web of Science ®Google Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55(10):4552-9
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382(9893):700-8
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Saita D, et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother 2013;68(11):2525-32
   PubMed Web of Science ®Google Scholar
• Pappa K, Baumgarten A, Felizarta F, et al. Dolutegravir (DTG) + Abacavir/Lamivudine Once Daily Superior to Tenofovir/Emtricitabine/Efavirenz in Treatment Naive HIV Subjects: 144-Week Results from SINGLE (ING114467). 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC 2014:Abstract H-647a
   Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13(11):927-35
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc 2014;17(4 Suppl 3):19490
   PubMedGoogle Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014;210(3):354-62
   PubMed Web of Science ®Google Scholar
• Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther 2014
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207(5):740-8
   PubMed Web of Science ®Google Scholar
• Llibre JM, Pulido F, Garcia F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev 2015;17(1):56-64
   PubMed Web of Science ®Google Scholar
• Quashie PK, Mesplede T, Wainberg MA. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 2013;26(1):43-9
   PubMed Web of Science ®Google Scholar
• Grobler JA, Hazuda DJ. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Current opinion in virology 2014;8:98-103
   PubMed Web of Science ®Google Scholar
• White KL, Raffi F, Miller MD. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients. Viruses 2014;6(7):2858-79
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27(11):1771-8
   PubMed Web of Science ®Google Scholar
• Eron J, Rockstroh J, Pozniak A, et al. Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment-naive HIV-infected individuals. 11th International Congress on Drug Therapy in HIV Infection. Glasgow, UK 2012;Poster Abstract P204
   Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014;383(9936):2222-31
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS 2015;29(2):167-74
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-40
   PubMed Web of Science ®Google Scholar
• Gutierrez Mdel M, Mateo MG, Vidal F, Domingo P. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf 2014;13(4):431-45
   PubMed Web of Science ®Google Scholar
• Lee FJ, Carr A. Tolerability of HIV integrase inhibitors. Curr Opin HIV AIDS 2012;7(5):422-8
   PubMed Web of Science ®Google Scholar
• Curtis L, Nichols G, Stainsby C, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials 2014;15(5):199-208
   PubMed Web of Science ®Google Scholar
• Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013;75(4):990-6
   PubMed Web of Science ®Google Scholar
• Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004;21(6):976-81
   PubMed Web of Science ®Google Scholar
• Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-Naive, HIV-1-Infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin drug investig 2015;35(3):211-19
   PubMed Web of Science ®Google Scholar
• Chen S, Min SS, Peppercorn A, et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy 2012;32(4):333-9
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30(5):1302-6
   PubMed Web of Science ®Google Scholar
• Min S, Roberts J, Almond S, et al. Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program. 20th International AIDS Conference. Melbourne, Australia 2014:WEPE062
   Google Scholar
• Kwakwa H, Spencer D, Evans C, et al. Gender differences in virologic outcomes in a meta-analysis of randomized controlled clinical trials in HIV-1-infected patients on antiretroviral therapy. XIX International AIDS Conference. Washington DC, USA 2012:Poster THPE041
   Google Scholar
• Song I, Mark S, Borland J, et al. Dolutegravir has no effect on the pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA 2013
   Google Scholar
• DHHS. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014.p.1–225. Available from: http://aidsinfonihgov/contentfiles/lvguidelines/perinatalglpdf http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf [Cited 4 December 2014]
   Google Scholar
• Viani RM, Alvero C, Fenton T, et al. Safety and efficacy of dolutegravir in HIV treatment-experienced adolescents: 48-week result. 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA 2014:Abstract 906LB
   Google Scholar
• Viani RM, Alvero C, Fenton T, et al. Safety pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV+ children [abstract 901]. 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA 2014
   Google Scholar
• Patel P, Song I, Borland J, et al. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects. Antivir Ther 2014;19(3):229-33
   PubMed Web of Science ®Google Scholar
• Eron JJJr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, et al. Virological efficacy of abacavir: systematic review and meta-analysis. J Antimicrob Chemother 2014;69(12):3169-80
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-40
   PubMed Web of Science ®Google Scholar
• FDA. Epzicom: Prescribing information. 2012. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [cited 21 January 2015]
   Google Scholar
• EMA. Kivexa; Summary of Product Characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000581/WC500043730.pdf [Cited 21 January 2015]
   Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-26
   PubMed Web of Science ®Google Scholar
• Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25(16):1993-2004
   PubMed Web of Science ®Google Scholar
• Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012;61(4):441-7
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Fletcher C, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009;53(4):1532-8
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004;48(1):176-82
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011;55(7):3517-21
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59(5):550-8
   PubMed Web of Science ®Google Scholar
• Weller S, Borand L, Wynne B, et al. Effect of Carbamazepine (CBZ) on Dolutegravir (DTG) Pharmacokinetics (PK) [abstract H-1013]. Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington DC 2014
   Google Scholar
• Chtioui H, Millius C, Lammle B, Lauterburg BH. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br J Haematol 2009;144(1):136-7
   PubMed Web of Science ®Google Scholar
• FDA. Triumeq: Prescribing Information. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205551s000lbl.pdf [Cited 15 February 2015]
   Google Scholar
• Song I, Mark S, Chen S, et al. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend 2013;133(2):781-4
   PubMed Web of Science ®Google Scholar
• Sellers E, Lam R, McDowell J. The pharmacokinetics (PK) of abacavir and methadone (M) following co-administration: CNAA1012 [abstract 663]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA 1999
   Google Scholar